Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ROIV |
---|---|---|
09:32 ET | 45625 | 11.33 |
09:34 ET | 4350 | 11.29 |
09:36 ET | 10648 | 11.305 |
09:38 ET | 7603 | 11.31 |
09:39 ET | 6920 | 11.32 |
09:41 ET | 5111 | 11.325 |
09:43 ET | 10982 | 11.315 |
09:45 ET | 1867 | 11.315 |
09:48 ET | 46852 | 11.33 |
09:50 ET | 4739 | 11.325 |
09:52 ET | 10130 | 11.335 |
09:54 ET | 6417 | 11.335 |
09:56 ET | 9705 | 11.325 |
09:57 ET | 5094 | 11.31 |
09:59 ET | 22627 | 11.32 |
10:01 ET | 16610 | 11.325 |
10:03 ET | 6598 | 11.315 |
10:06 ET | 11976 | 11.32 |
10:08 ET | 21531 | 11.355 |
10:10 ET | 39627 | 11.34 |
10:12 ET | 12923 | 11.355 |
10:14 ET | 2060 | 11.355 |
10:15 ET | 18552 | 11.365 |
10:17 ET | 28992 | 11.365 |
10:19 ET | 60431 | 11.375 |
10:21 ET | 83832 | 11.37 |
10:24 ET | 57623 | 11.35 |
10:26 ET | 16232 | 11.31 |
10:28 ET | 23532 | 11.295 |
10:30 ET | 22854 | 11.29 |
10:32 ET | 26722 | 11.315 |
10:33 ET | 18796 | 11.325 |
10:35 ET | 24031 | 11.35 |
10:37 ET | 17410 | 11.345 |
10:39 ET | 20422 | 11.325 |
10:42 ET | 21791 | 11.345 |
10:44 ET | 18920 | 11.335 |
10:46 ET | 18413 | 11.335 |
10:48 ET | 31039 | 11.32 |
10:50 ET | 5137 | 11.315 |
10:51 ET | 8815 | 11.335 |
10:53 ET | 17247 | 11.345 |
10:55 ET | 7689 | 11.335 |
10:57 ET | 15134 | 11.335 |
11:00 ET | 4189 | 11.33 |
11:02 ET | 32391 | 11.345 |
11:04 ET | 9741 | 11.345 |
11:06 ET | 18560 | 11.335 |
11:08 ET | 17767 | 11.335 |
11:09 ET | 4638 | 11.345 |
11:11 ET | 3396 | 11.345 |
11:13 ET | 2351 | 11.35 |
11:15 ET | 24564 | 11.33 |
11:18 ET | 2793 | 11.32 |
11:20 ET | 4521 | 11.315 |
11:22 ET | 9366 | 11.3 |
11:24 ET | 4976 | 11.285 |
11:26 ET | 3915 | 11.28 |
11:27 ET | 5307 | 11.275 |
11:29 ET | 3131 | 11.28 |
11:31 ET | 4200 | 11.28 |
11:33 ET | 26084 | 11.275 |
11:36 ET | 25281 | 11.265 |
11:38 ET | 15443 | 11.26 |
11:40 ET | 1055 | 11.26 |
11:42 ET | 19431 | 11.255 |
11:44 ET | 4493 | 11.275 |
11:45 ET | 16774 | 11.27 |
11:47 ET | 3570 | 11.27 |
11:49 ET | 1665 | 11.2766 |
11:51 ET | 6500 | 11.26 |
11:54 ET | 10383 | 11.255 |
11:56 ET | 8106 | 11.265 |
11:58 ET | 2442 | 11.265 |
12:00 ET | 9240 | 11.265 |
12:02 ET | 11931 | 11.28 |
12:03 ET | 4446 | 11.29 |
12:05 ET | 1300 | 11.28 |
12:07 ET | 13730 | 11.285 |
12:09 ET | 6756 | 11.275 |
12:12 ET | 10573 | 11.275 |
12:14 ET | 2773 | 11.285 |
12:16 ET | 1400 | 11.285 |
12:18 ET | 3901 | 11.295 |
12:20 ET | 13525 | 11.28 |
12:21 ET | 1000 | 11.2888 |
12:23 ET | 2509 | 11.285 |
12:25 ET | 11680 | 11.275 |
12:27 ET | 11702 | 11.265 |
12:30 ET | 1083 | 11.265 |
12:32 ET | 2671 | 11.26 |
12:34 ET | 6774 | 11.265 |
12:36 ET | 1816 | 11.27 |
12:38 ET | 17574 | 11.275 |
12:39 ET | 3609 | 11.285 |
12:41 ET | 1696 | 11.2893 |
12:43 ET | 10498 | 11.295 |
12:45 ET | 10568 | 11.295 |
12:48 ET | 5315 | 11.3 |
12:50 ET | 1606 | 11.3 |
12:52 ET | 25416 | 11.285 |
12:54 ET | 18224 | 11.285 |
12:56 ET | 21382 | 11.29 |
12:57 ET | 1840 | 11.285 |
12:59 ET | 13406 | 11.275 |
01:01 ET | 5758 | 11.28 |
01:03 ET | 2089 | 11.285 |
01:06 ET | 26648 | 11.285 |
01:08 ET | 1146 | 11.285 |
01:10 ET | 1120 | 11.285 |
01:12 ET | 28181 | 11.285 |
01:14 ET | 13060 | 11.3 |
01:15 ET | 9599 | 11.3 |
01:17 ET | 2157 | 11.295 |
01:19 ET | 18364 | 11.315 |
01:21 ET | 2700 | 11.315 |
01:24 ET | 11060 | 11.315 |
01:26 ET | 22353 | 11.315 |
01:28 ET | 10659 | 11.3 |
01:30 ET | 1407 | 11.305 |
01:32 ET | 20266 | 11.305 |
01:33 ET | 3541 | 11.3 |
01:35 ET | 11775 | 11.305 |
01:37 ET | 17351 | 11.29 |
01:39 ET | 53063 | 11.295 |
01:42 ET | 5787 | 11.295 |
01:44 ET | 2012 | 11.295 |
01:46 ET | 3074 | 11.295 |
01:48 ET | 23504 | 11.285 |
01:50 ET | 11814 | 11.295 |
01:51 ET | 40291 | 11.29 |
01:53 ET | 10746 | 11.28 |
01:55 ET | 2776 | 11.29 |
01:57 ET | 25605 | 11.3 |
02:00 ET | 28219 | 11.29 |
02:02 ET | 5027 | 11.29 |
02:04 ET | 4681 | 11.2999 |
02:06 ET | 8376 | 11.29 |
02:08 ET | 18779 | 11.285 |
02:09 ET | 10294 | 11.285 |
02:11 ET | 576 | 11.28 |
02:13 ET | 15122 | 11.295 |
02:15 ET | 40640 | 11.285 |
02:18 ET | 7669 | 11.295 |
02:20 ET | 8753 | 11.295 |
02:22 ET | 2106 | 11.295 |
02:24 ET | 5473 | 11.3 |
02:26 ET | 16375 | 11.32 |
02:27 ET | 6421 | 11.315 |
02:29 ET | 3401 | 11.31 |
02:31 ET | 27008 | 11.305 |
02:33 ET | 37418 | 11.305 |
02:36 ET | 3843 | 11.305 |
02:38 ET | 7056 | 11.315 |
02:40 ET | 24097 | 11.305 |
02:42 ET | 3221 | 11.305 |
02:44 ET | 10879 | 11.315 |
02:45 ET | 3073 | 11.315 |
02:47 ET | 11709 | 11.325 |
02:49 ET | 33763 | 11.335 |
02:51 ET | 37926 | 11.345 |
02:54 ET | 44013 | 11.345 |
02:56 ET | 2328 | 11.345 |
02:58 ET | 6307 | 11.35 |
03:00 ET | 18720 | 11.355 |
03:02 ET | 8438 | 11.35 |
03:03 ET | 7636 | 11.35 |
03:05 ET | 10854 | 11.355 |
03:07 ET | 2752 | 11.355 |
03:09 ET | 17943 | 11.365 |
03:12 ET | 126168 | 11.35 |
03:14 ET | 31273 | 11.345 |
03:16 ET | 3937 | 11.34 |
03:18 ET | 20652 | 11.3561 |
03:20 ET | 14929 | 11.355 |
03:21 ET | 54129 | 11.36 |
03:23 ET | 14601 | 11.365 |
03:25 ET | 21305 | 11.365 |
03:27 ET | 34987 | 11.355 |
03:30 ET | 5019 | 11.35 |
03:32 ET | 10766 | 11.355 |
03:34 ET | 4608 | 11.37 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Roivant Sciences Ltd | 8.3B | 2.0x | --- |
Corcept Therapeutics Inc | 4.7B | 39.9x | +9.80% |
Ligand Pharmaceuticals Inc | 1.9B | 47.3x | -12.71% |
Harrow Inc | 1.8B | -53.1x | --- |
Ocular Therapeutix Inc | 1.4B | -9.0x | --- |
Immunocore Holdings PLC | 1.5B | -29.2x | --- |
Roivant Sciences Ltd. is a commercial-stage biopharmaceutical company that seeks to improve the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting the neonatal Fc receptor (FcRn) in development across several IgG-mediated autoimmune indications; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 for the treatment of dermatomyositis and non-infectious uveitis, in addition to other clinical-stage molecules. It advances its pipeline by creating nimble subsidiaries or Vants to develop and commercialize its medicines and technologies. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its pipeline program also includes Mosliciguat.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $8.3B |
---|---|
Revenue (TTM) | $158.3M |
Shares Outstanding | 739.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.25 |
EPS | $5.57 |
Book Value | $7.40 |
P/E Ratio | 2.0x |
Price/Sales (TTM) | 52.4 |
Price/Cash Flow (TTM) | 1.8x |
Operating Margin | 2,799.07% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.